Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Comments
Loading...
Virtus LifeSci Biotech Clinical Trials ETF Stock Price, Quotes and Forecasts
BBCARCA
Edge Rankings
Stock Score Locked: Edge Members Only
Benzinga Rankings give you vital metrics on any stock – anytime.
Sector
Healthcare
Region
US
AUM
9.79M
Fund Score
Virtus LifeSci Biotech Clinical Trials ETF Price, Quotes and Forecasts | ARCA:BBC | Benzinga
Explore Virtus LifeSci Biotech Clinical Trials ETF stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for BBC.
| Open | $18.21 |
| High | $18.40 |
| 52 Wk High | $31.65 |
| AUM | 9.79M |
| Dividend | $0.24 |
| Ex-Div Date | Dec 20, 2024 |
| Volume | 31.12K |
| Market Cap | $1.80B |
| Mgmt Fee | 0.79% |
| P/E Ratio | 9.14 |
| Prev. Close | $18.05 |
| Low | $18.00 |
| 52 Wk Low | $13.42 |
| Shares Out | 400.00K |
| Yield | 1.33% |
| Div. Freq | Annual |
| Avg. Volume Daily | 96.51K |
| Beta | 0.97 |
| Avg. Expense Ratio | 0.79% |
| P/B Ratio | 2.48 |
Recent News
FAQ
Q
How do I buy Virtus LifeSci Biotech Clinical Trials ETF (BBC) stock?
A
You can purchase shares of Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC) through any online brokerage.
Q
Who are Virtus LifeSci Biotech Clinical Trials ETF (BBC) competitors?
A
There are no as such competitors for Virtus LifeSci Biotech Clinical Trials ETF.
Q
What is the forecast, or price target, for Virtus LifeSci Biotech Clinical Trials ETF (BBC) stock?
A
There is no analysis for Virtus LifeSci Biotech Clinical Trials ETF to provide a consensus price target.
Q
What is the current price for Virtus LifeSci Biotech Clinical Trials ETF (BBC)?
A
The stock price for Virtus LifeSci Biotech Clinical Trials ETF (ARCA: BBC) is $18.28 last updated May 20, 2025 at 12:25 PM EDT.
Q
Does Virtus LifeSci Biotech Clinical Trials ETF (BBC) pay a dividend?
A
A quarterly cash dividend of 0.30 per share of Class A Common Stock. The quarterly cash dividend was payable on December 27, 2017 to stockholders of record on December 20, 2017.
Q
When is Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC) reporting earnings?
A
Virtus LifeSci Biotech Clinical Trials ETF does not have any upcoming earnings scheduled.
Q
Is Virtus LifeSci Biotech Clinical Trials ETF (BBC) going to split?
A
There is no upcoming split for Virtus LifeSci Biotech Clinical Trials ETF.
| Open | $18.21 |
| High | $18.40 |
| 52 Wk High | $31.65 |
| AUM | 9.79M |
| Dividend | $0.24 |
| Ex-Div Date | Dec 20, 2024 |
| Volume | 31.12K |
| Market Cap | $1.80B |
| Mgmt Fee | 0.79% |
| P/E Ratio | 9.14 |
| Prev. Close | $18.05 |
| Low | $18.00 |
| 52 Wk Low | $13.42 |
| Shares Out | 400.00K |
| Yield | 1.33% |
| Div. Freq | Annual |
| Avg. Volume Daily | 96.51K |
| Beta | 0.97 |
| Avg. Expense Ratio | 0.79% |
| P/B Ratio | 2.48 |
About ETFis Series Trust I
Sector
N/A
Industry
N/A
ETF Details
| Sector | Healthcare |
| Category | High Performer-Mid Growth |
| Investment Style | Small Cap Growth |
| Fund Inception | Dec 16, 2014 |
| Managers | Seth Kadushin Paul Yook Andrew McDonald Matthew B. Brown |
| Definition | This equity fund portfolio contains majority of stocks with strong financial performance and average growth potential |
Investment Policy
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| RNA | Avidity Biosciences In... | 2.84% |
| SMMT | Summit Therapeutics In... | 1.47% |
| VKTX | Viking Therapeutics In... | 2.75% |
| CGEM | Cullinan Oncology Inc | 2.34% |
| DYN | Dyne Therapeutics Inc | 2.29% |
| NVAX | Novavax Inc | 2.24% |
| VERA | Vera Therapeutics Inc ... | 2.19% |
| SYRE | Spyre Therapeutics Inc | 0.76% |
| MRUS | Merus Nv | 1.13% |
| ACLX | Arcellx, Inc. | 1.36% |
| BLTE | Belite Bio, Inc | 1.09% |
| SLRN | Acelyrin Inc | 0.90% |
| NAMS | Newamsterdam Pharma Co... | 0.88% |
| MLYS | Mineralys Therapeutics... | 1.31% |
| NMRA | Neumora Therapeu | 0.86% |
| GPCR | Structure Therapeutics... | 0.55% |
| NGNE | Neurogene Inc - Series... | 0.52% |
| PRME | Prime Medicine, Inc. | 0.36% |
| AKRO | Akero Therapeutics Inc | 1.67% |
| LQDA | Liquidia Corp | 1.35% |
| SANA | Sana Biotechnology Inc | 1.26% |
| ARQT | Arcutis Biotherapeutic... | 1.28% |
| ANAB | Anaptysbio Inc | 1.54% |
| XERS | Xeris Biopharma Holdin... | 1.41% |
| VIR | Vir Biotechnology Inc | 1.12% |
| ETNB | 89bio Inc | 1.11% |
| SLNO | Soleno Therapeutics In... | 1.73% |
| PTGX | Protagonist Therapeuti... | 1.19% |
| RGNX | Regenxbio Inc | 1.20% |
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved